Kisspeptin
The upstream master regulator of reproduction — full-length form studied for HPG axis restoration and IVF enhancement.
Research facts
| Half-life | ~4 minutes (IV) / longer SubQ |
|---|---|
| Route | IV / SubQ |
| Typical dose | 1–10 nmol/kg (per research protocol) |
| Frequency | Pulsatile or bolus per protocol |
| Solvent | Bacteriostatic water |
| pH | 5.5–7.5 |
| Stability | 30 days at +4°C |
Mechanism of action
Kisspeptin-54 is the full-length endogenous kisspeptin (the 54-amino acid form processed from the KISS1 protein). It shares the same KISS1R receptor as Kisspeptin-10 but has a longer half-life and potentially broader physiological effects. Human Phase I/II trials have used kisspeptin-54 for ovarian hyperstimulation triggering in IVF (a safer alternative to hCG, avoiding OHSS), hypothalamic amenorrhoea treatment, and HPG axis investigation. The IVF application is the most clinically advanced.
Documented effects (research-model)
- IVF ovulation trigger — Phase II: safer than hCG (no OHSS)
- HPG axis investigation and restoration research
- Hypothalamic amenorrhoea reversal (Phase II data)
- Longer half-life than Kisspeptin-10 for sustained LH stimulation
Research protocols
| Protocol | Dose | Frequency | Cycle | Vial |
|---|---|---|---|---|
| IVF Trigger (Research) | Weight-based IV bolus (Phase II protocol) | Single trigger dose in IVF | N/A | Research preparation |
Research context only. Not medical advice. Consult a qualified healthcare professional before any protocol decision.
Synergies
- Gonadorelin HIGH
Kisspeptin-54 (upstream GnRH driver) + Gonadorelin (direct GnRH delivery). Complementary HPG axis stimulation.
Myths & misconceptions
Evidence gaps
- Phase III IVF trials vs. hCG as standard trigger in different patient populations.
- Long-term fertility outcomes after kisspeptin-triggered IVF cycles.
Safety notes
Phase II safety data shows good tolerability. IVF trigger application: appears safe with markedly reduced OHSS risk vs. hCG. Research context for non-IVF applications.
Biomarkers to monitor
Primary-source citations
- PMID 22628511 — Kisspeptin triggers oocyte maturation in women undergoing in vitro fertilization (N Engl J Med. 2012)
Frequently asked
What is Kisspeptin?
Kisspeptin (Full-Length Kisspeptin-54 — KISS1 Protein) is a research compound classified in our library as Tier C — Limited human trials; effect size uncertain.. The upstream master regulator of reproduction — full-length form studied for HPG axis restoration and IVF enhancement.
What is the evidence tier for Kisspeptin?
We classify Kisspeptin as Tier C: Limited human trials; effect size uncertain. See our full peptide evidence tiers explainer for how we assign S/A/B/C/D.
What is the research dose of Kisspeptin?
For Kisspeptin, typical research dose is 1–10 nmol/kg (per research protocol), route is IV / SubQ, half-life is ~4 minutes (IV) / longer SubQ. Protocols vary by research goal — see the protocols section on this page for standard and advanced dosing schedules. Research use only, not medical advice.
What does Kisspeptin stack well with?
Kisspeptin stacks well with Gonadorelin. Kisspeptin-54 (upstream GnRH driver) + Gonadorelin (direct GnRH delivery). Complementary HPG axis stimulation.
Is Kisspeptin safe?
Phase II safety data shows good tolerability. IVF trigger application: appears safe with markedly reduced OHSS risk vs. Research context only — no compound on this site is approved for human therapeutic use unless explicitly noted.